Back to Search
Start Over
C3 glomerulopathy [version 1; referees: 4 approved]
- Source :
- F1000Research. 6:F1000 Faculty Rev-248
- Publication Year :
- 2017
- Publisher :
- London, UK: F1000 Research Limited, 2017.
-
Abstract
- C3 glomerulopathy is a recently defined entity that encompasses a group of kidney diseases caused by abnormal control of complement activation with deposition of complement component C3 in glomeruli leading to variable glomerular inflammation. Before the recognition of the unique pathogenesis of these cases, they were variably classified according to their morphological features. C3 glomerulopathy accounts for roughly 1% of all renal biopsies. Clear definition of this entity has allowed a better understanding of its pathogenesis and clinical course and is likely to lead to the design of rational therapies over the next few years.
- Subjects :
- Review
Articles
Genetics of the Immune System
Hereditary, Genetic & Developmental Aspects of Nephrology
Immunopharmacology & Hematologic Pharmacology
Innate Immunity
Medical Genetics
Renal Immunology & Pathology (incl. Glomerular Diseases)
Renal Pharmacology
C3 complement
glomerular inflammation
renal pathology
Subjects
Details
- ISSN :
- 20461402
- Volume :
- 6
- Database :
- F1000Research
- Journal :
- F1000Research
- Notes :
- Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: John D. Lambris, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA Competing interests: J.D.L is an inventor of patents and patent application describing complement inhibitors and their clinical use. He is also the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes. Minghui Zhao, Renal Division, Peking University First Hospital, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing, China No competing interests were disclosed. Francesco Emma, Department of Nephrology and Urology, Division of Nephrology, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy No competing interests were disclosed. Marina Vivarelli, Department of Nephrology and Urology, Division of Nephrology, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy No competing interests were disclosed. Arvind Bagga, Division of Pediatric Nephrology, All India Institute of Medical Sciences, New Delhi, India No competing interests were disclosed., , [version 1; referees: 4 approved]
- Publication Type :
- Academic Journal
- Accession number :
- edsfor.10.12688.f1000research.10364.1
- Document Type :
- review
- Full Text :
- https://doi.org/10.12688/f1000research.10364.1